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Abstract
Objective: Artificial dermal substitutes (DSs) are fundamental in physiological wound healing to
ensure consistent and enduring wound closure and provide a suitable scaffold to repair tissue.
We compared the clinical and histological features of two DSs, Pelnac and Integra, in the treat-
ment of traumatic and iatrogenic skin defects.
Methods: This prospective observational study involved 71 randomly selected patients from our
hospital. Wound healing was analyzed using the Wound Surface Area Assessment, the Vancouver
Scar Scale, and a visual analog scale. Histological and immunohistochemical evaluations were also
performed.
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Results: At 2 weeks, greater regeneration with respect to proliferation of the epidermis and
renewal of the dermis was observed with Pelnac than with Integra. At 4 weeks, the dermis had
regenerated with both DSs. Both templates induced renewed collagen and revascularization.
Differences in the Vancouver Scar Scale score were statistically significant at 4 weeks and 1
year. Pelnac produced a significant increase in contraction at 2 weeks with increasing effectiveness
at 4 weeks. Integra produced a higher percentage reduction in the wound surface area and a
shorter healing time than Pelnac for wounds >1.5 cm deep.
Conclusion: Our observational data indicate that both DSs are effective and applicable in dif-
ferent clinical contexts.
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Introduction
The skin is an important organ in the
defense against microorganisms, conserva-
tion of body temperature, and detection of
external sensory stimuli. Acute trauma,
chronic wounds, or surgical interventions
may cause skin loss and interfere with epi-
thelial regeneration by inducing full-
thickness wounds; skin recovery then
mainly occurs from the wound edge with
poor cosmetic or functional outcomes.1,2
The healing process involves three stages
of achieving tissue integrity and homeosta-
sis: inflammation, tissue formation, and
tissue remodeling.3 Wound healing and
tissue generation in dermal injuries involve
functional and cosmetic processes that are
akin to the mechanisms occurring in
unwounded dermis processes with a com-
plex organization among multiple types of
cells, bioactive molecules, and extracellular
matrix (ECM) components.4
Notwithstanding the potential of full-
thickness skin wounds exceeding 1 cm in
diameter to self-epithelialize, adequate
wound care is certainly fundamental in the
form of moist dressings, infection control,
and offloading or compression bandaging,
depending on the wound type. Moreover,
the wound healing process may result in
substantial scarring with subsequent limited
mobility and significant deformation, thus
requiring full-thickness skin grafting.5,6
Plastic surgeons may use bioengineering
replacement techniques, free flaps, and
autologous skin grafts to cover such inju-
ries. Skin grafting is certainly efficient and
widely used to close large wounds as well as
to repair a variety of acute and chronic
wound discrepancies. However, insufficient
availability of healthy skin and clinical
complications related to donor-site defor-
mation and morbidity are important conse-
quences of skin grafting. Successful grafting
will undoubtedly offer satisfactory out-
comes regarding functionality and cosme-
sis, but poor grafting may result in the
formation of ulcers, contractions, hypertro-
phy, and pigmentation. Encouraging
early results have spurred researchers to
widely investigate adequate graft beds con-
taining well-vascularized solid granulation
tissue.
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Scientists and surgeons have recently
considered various bioengineering and syn-
thetic approaches to regenerate skin inju-
ries. Tissue-engineered skin bio-constructs
have been confirmed as valid options to
manage donor-site anomalies in extensive
burn injuries as well as protect the wound
surface and generate ECM, thus providing
efficient healing potential in the recipient
site. Skin grafts contribute to decreasing
contraction and scar formation by eliciting
ECM remodeling and regeneration.7,8
Numerous tissue-engineered skin bio-
constructs are currently accessible as der-
moepidermal, epidermal, and dermal
replacements.9–11 Dermal substitutes (DSs)
are important skin replacements and play a
major role in repairing full-thickness skin
defects, improving long-term functional
and cosmetic outcomes, and providing sat-
isfactory scar quality.12 DSs are mass-
producible, effective, and easily stored and
handled; thus, they may be considered opti-
mal skin replacements. These substitutes
can be further divided into acellular and
synthetic materials, with the latter offering
a lower risk of human viral disease conta-
gion. Some DSs, such as Integra (Integra
LifeSciences, Princeton, NJ, USA) and
Pelnac (Gunze Corp., Osaka, Japan), have
a three-dimensional collagen structure and
contain a superficial silicone layer placed
within the defect area that protects against
dehydration, microorganisms, and toxins.
The collagen layer slowly integrates into
the wound, and natural recovery processes
are promoted via localized inflammation;
infiltration of neutrophils, macrophages,
fibroblasts, and keratinocytes; and neovas-
cularization of the scaffold.13 Differences in
DSs are likely to affect multiple wound-
healing mechanisms, including fibroplasia,
because the ECM provides porosity, elastic-
ity, and biocompatibility and may strongly
influence cellular migration, proliferation,
and differentiation during recovery.14–16
DSs physically differ based on the specific
manufacturing methods used.17
Biomaterials have been extensively investi-
gated for use in skin replacement, and acel-
lular DSs are fundamental to prepare the
wound bed and enhance graft integration
with the resultant recipient surface.
Moreover, DSs are able to repair
full-thickness cutaneous wounds and elicit
effective wound healing,18 and they are rec-
ommended in reconstructive surgery19–22
because they provide adequate scaffolding
to interpose fibroblasts and endothelial cells
toward neodermis formation.23–26
We conducted a randomized study to
compare Pelnac and Integra, the two
above-mentioned collagen acellular bilayer
substitutes used to treat a variety of skin
wounds. We have experience with these syn-
thetic DSs in the treatment of various skin
defects such as those caused by trauma-
related injuries, tumor removal or nevus
excision, contracture release, and full-
thickness wounds. Although no specific
DSs have yet been defined for different
types of wounds, we performed the present
study to investigate various post-treatment
skin graft contractions affecting patients
and herein report our in vitro analysis
results. This study was performed to com-
pare Pelnac and Integra from clinical, his-
tological, and immunohistochemical
perspectives for a period of 1 year.
Materials and methods
Patients
This prospective observational study was
conducted for a 1-year period and involved
patients presenting with partial- and
full-thickness post-traumatic wounds and
post-iatrogenic cutaneous defects. The inves-
tigationwas performed in compliancewith the
Declaration ofHelsinki and theGuidelines for
Good Clinical Practice. All participants pro-
vided written informed consent to undergo
surgery, follow-up, and biopsies.
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The inclusion criteria were Caucasian
patients of either sex, age of >18 to <85
years, wounds with surface dimensions of
2 1 to 35 20 cm, negative culture swab
before surgery, maximum wound depth of
2.5 cm, negative traditional markers of sys-
temic inflammation (C-reactive protein,
erythrocyte sedimentation rate, and procal-
citonin), post-traumatic or iatrogenic
wounds, and wounds presenting anywhere
on the entire exterior surface of the body
with the exception of the face and neck.
The exclusion criteria were chronic liver
disease, coagulopathy and/or anticoagulant
therapy, treatment with immunosuppres-
sive drugs and corticosteroids, smoking
habit, type 1 and 2 diabetes mellitus, onco-
logical disease in progression or remission,
immunodeficiency (congenital, acquired, or
metabolic), loss to follow-up, and incom-
plete medical/nursing records.
Following enrollment, the patients were
randomly assigned to two groups (those
treated with Pelnac and those treated with
Integra) (Table 1(a), (b)) on a computer-
generated list open to only one investigator
who was blinded to assessment and treat-
ment. Allocation was occasionally revealed
to surgeons but on no occasion to assessors.
When the DS stimulated dermal growth
to approximately the epidermal level, the
participants in both groups underwent sub-
sequent autologous dermoepidermal graft-
ing. We assessed the wound contracture
with respect to wound depth. Several
patients in each group who had deep
wounds (>1.5 cm) did not undergo auto-
grafting so that we could evaluate the dif-
ferent wound contraction capacities with
respect to the depth of the lesion.
DSs
Integra is widely used in the treatment of full-
thickness injuries. It consists of a bovine type
1 collagen bilayer attached to shark chon-
droitin 6-sulfate glycosaminoglycan
bonded to a temporary epidermal substitute
layer of pseudoepidermis in silicone. Pelnac
is a bilaminar membrane with a superficial
silicone film layer and a porcine collagen
sponge layer derived from pig tendon with
a pore diameter ranging from 60 to
110 mm. Details are provided in Table 2.
Clinical and surgical protocols
We assessed all patients for comorbidities
and examined their wounds according to
our protocol, which involved a swab cul-
ture, instrumental evaluation, and photo-
graphs. Instrumental laser Doppler
measurements for vascular pathology were
not performed. A short-term follow-up was
performed at 2 and 4 weeks after DS
implantation, and a long-term follow-up
was performed at 1 year. The silicone
layer was removed after 2 weeks following
Pelnac implantation and after 4 weeks fol-
lowing Integra implantation as suggested
by the manufacturers. In both groups, the
dermoepidermal grafts were applied within
1 week after silicone removal. During
follow-up, photographs were taken before
and after application of the dermoepider-
mal grafts. We treated traumatic wounds
by preparing the wound bed via debride-
ment, bacterial balance, and exudate man-
agement. A swab culture was performed to
check for the presence of microbiological
infections and identify relevant antibiotic
treatment if required. DS implants require
an effective wound bed site to ensure opti-
mal reception. We conducted these proce-
dures under locoregional anesthesia or
sedation in strictly aseptic conditions. We
first debrided the damaged tissues and
then applied the DS; the subsequent split-
thickness dermoepidermal grafts were
applied 21 or 30 days later, after removing
the silicone layer. In patients with tumors,
we performed wide excision of the neoplasia
including healthy perilesional tissue and
extending to the underlying fascia or
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muscle if necessary. We then covered the
substance loss with the Pelnac or Integra
DS and proceeded with application of
split-thickness dermoepidermal grafts 21
or 30 days later, respectively, after remov-
ing the silicone layer. We performed classic
dermatome skin grafting using thin split-
thickness skin grafts, meshing the grafts at
a 1:2 ratio. The grafts were applied to the
wounds with 3/0 nylon sutures or metallic
staples. The wound was covered with a
moulage compressive dressing and sterile
gauze.
Clinical criteria evaluation during
treatment and follow-up
The clinical assessment was based on the
healing time after dermoepidermal graft
application, the Wound Surface Area
Table 1(a). Pelnac group.
Patient Age (years) Pathology Wound localization Wound area (cm)
1 23 Post-traumatic Finger 4 2
2 56 Iatrogenic Right shoulder 13 9
3 45 Iatrogenic Forearm 9 5
4 40 Iatrogenic Finger 3 1
5 21 Post-traumatic Right foot 10 4
6 60 Post-traumatic Left leg 15 9
7 79 Post-traumatic Left leg 6 4
8 75 Iatrogenic Forearm 7 4
9 35 Post-traumatic Left thigh 28 15
10 38 Iatrogenic Right foot 9 4
11 49 Post-traumatic Finger 3 2
12 57 Iatrogenic Left hypogastrium 15 12
13 51 Post-traumatic Left leg 14 7
14 65 Post-traumatic Elbow 4 4
15 61 Post-traumatic Finger 2 2
16 48 Iatrogenic Left leg 12 9
17 45 Iatrogenic Right leg 12 6
18 83 Post-traumatic Left leg 6 5
19 40 Iatrogenic Right foot 8 7
20 47 Iatrogenic Hand 7 6
21 60 Iatrogenic Right foot 8 5
22 67 Post-traumatic Forearm 12 4
23 58 Iatrogenic Hand 6 6
24 69 Iatrogenic Chest 13 10
25 61 Post-traumatic Forearm 7 4
26 82 Iatrogenic Scalp 17 12
27 35 Post-traumatic Right ankle 8 3
28 67 Iatrogenic Abdomen 9 3
29 66 Iatrogenic Left ankle 6 2
30 28 Iatrogenic Scalp 7 7
31 50 Post-traumatic Right leg 4 3
32 53 Iatrogenic Left knee 4 3
33 76 Iatrogenic Scalp 5 3
34 60 Post-traumatic Left leg 17 7
35 40 Iatrogenic Right arm 13 10
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Assessment, the Vancouver Scar Scale
(VSS), and a visual analog scale (VAS) for
pain. Moreover, the color shift of the colla-
gen layer in both DSs was analyzed to exam-
ine the graft and collagen maturation,
appropriate disposition of the DS, and ade-
quate reception of the dermoepidermal
grafting. In all patients, we monitored the
wound surface for contraction at 1 week
and every week until complete healing. We
traced the wound edges via digital photog-
raphy. Computer-based planimetry was
used to assess wound contraction, measur-
ing the reduction percentage of the initial
wound surface area. At each follow-up, we
recorded adverse effects and complications
and assessed pain following DS implanta-
tion via the VAS. Patients were required to
Table 1(b). Integra group.
Patient Age (years) Pathology Wound localization Wound area (cm)
1 67 Iatrogenic Hand 4 4
2 56 Iatrogenic Right shoulder 13 9
3 86 Iatrogenic Abdomen 10 6
4 29 Post-traumatic Finger 4 2
5 37 Post-traumatic Left leg 13 6
6 74 Iatrogenic Forearm 7 3
7 56 Iatrogenic Abdomen 10 8
8 59 Post-traumatic Right foot 8 6
9 35 Post-traumatic Abdomen 29 14
10 39 Post-traumatic Finger 2 2
11 78 Iatrogenic Right leg 12 5
12 72 Iatrogenic Left thigh 20 10
13 65 Iatrogenic Hand 5 5
14 55 Post-traumatic Forearm 7 4
15 59 Iatrogenic Hand 4 4
16 51 Post-traumatic Left leg 9 7
17 47 Post-traumatic Right leg 5 3
18 32 Post-traumatic Right foot 8 7
19 45 Iatrogenic Finger 2 2
20 73 Iatrogenic Forearm 12 4
21 47 Post-traumatic Right leg 9 6
22 50 Post-traumatic Right leg 12 6
23 61 Iatrogenic Hand 5 4
24 42 Post-traumatic Finger 2 2
25 40 Post-traumatic Hand 6 6
26 48 Post-traumatic Left leg 4 2
27 45 Iatrogenic Trunk 36 16
28 55 Iatrogenic Left thigh 7 4
29 40 Post-traumatic Right foot 4 2
30 19 Post-traumatic Right leg 8 3
31 51 Post-traumatic Right foot 10 9
32 42 Post-traumatic Foot 10 20
33 83 Iatrogenic Scalp 9 10
34 48 Iatrogenic Forearm 12 7
35 65 Post-traumatic Left leg 6 5
36 55 Post-traumatic Left leg 9 4
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complete the VAS by placing a line perpen-
dicular to the VAS line corresponding to
their pain intensity. We recorded the result
on a scale ranging from 0 to 10 in which 0
indicated no pain and 10 indicated intense
pain. The functional and aesthetic outcomes
of re-epithelialization (healing time) were
assessed by a blinded plastic surgeon
according to the VSS (height, pliability, vas-
cularization, and scar pigmentation) at the
time of healing and at the 1-year follow-up.
The patients self-estimated their func-
tional and aesthetic outcomes. Results
were graded from 1 to 4 (1, very disappoint-




Excised tissues were fixed in 10% formalin
solution for 24 hours. Tissues were embed-
ded in paraffin wax, sectioned at 7-mm
thickness, assembled on glass slides, depar-
affinized, then stained with hematoxylin–
eosin and Van Gieson (Bio-Optica, Milan,
Italy) for collagen analysis.
Immunohistochemistry samples were
fixed in 40 g/L formaldehyde and processed
by paraffin embedding using standard meth-
ods. Sections were cut to 7-mm thickness,
placed on polylysine-coated microscope
slides, and processed for collagen type I, col-
lagen type III, vascular endothelial growth
factor (VEGF), CD68, and intracellular
adhesion molecule 1 (ICAM-1). The sec-
tions were deparaffinized in xylene, rehy-
drated, and placed in a microwave oven at
800 W for three 5-minute cycles in 0.01 mol/
L citrate buffer (pH 6) to maximize antigen
retrieval. Endogenous peroxidase activity
was interrupted by slide incubation in 30
mL/L hydrogen peroxide (3% in methanol)
for 30 minutes. The slides were rinsed in
phosphate-buffered saline and then incubat-
ed with blocking solution (3 mL/L Triton X-
100, 10 g/L bovine serum albumin, and 10
mL/L normal swine or rabbit serum); the
solution served as an antibody dilution.
The sections were then placed in an incuba-
tor with the following primary antibodies
overnight at 4C: rabbit anti-collagen type
I, dilution 1:500 (GTX41286; GeneTex,
Irvine, CA, USA); mouse anti-collagen
type III, dilution 1:1000 (GTX26310;
GeneTex); mouse anti-VEGF, dilution
1:100 (GTX83426; GeneTex); mouse anti-
CD68, dilution 1:200 (M0876; Dako,
Table 2. Details of Integra and Pelnac groups.
INTEGRA PELNAC
Integra (Integra LifeSciences, Princeton, NJ, USA)
is a double-layer membrane system in which
the deep layer is composed of bovine type I
collagen fibers linked to shark chondroitin
6-sulfate glycosaminoglycan linked to a silicone
replacement layer.
Pelnac (Gunze Corp., Osaka, Japan) is a bilaminar
membrane with a surface layer of silicone film
and a layer of porcine collagen sponge derived
from the pork tendon.
Epidermis: Silicone Epidermis: Silicone
Dermis/Matrix: Three-dimensional porous matrix
of cross-linked collagen and glycosaminoglycan
Dermis/Matrix: Atelocollagen sponge not cross-
linked and without glycosaminoglycan
Composition: Bovine collagen with chondroitin
6-sulfate
Composition: Porcine collagen
Type of collagen: Collagen types I and III Type of collagen: Collagen type I
Extraction: Bovine tendon Extraction: Porcine tendon
Cost (our hospital): 1008 e/100 cm2 Cost (our hospital): 753 e/100 cm2
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Glostrup, Denmark); and rabbit anti-
ICAM-1, dilution 1:100 (AD062401;
eBioscience, San Diego, CA, USA). The sec-
tions were then reacted with biotinylated
secondary antibody (anti-rabbit antibody
diluted 1:400 for collagen type I and
ICAM-1; anti-mouse antibody diluted
1:400 for collagen type III, VEGF, and
CD68) for 1 hour at room temperature.
The immunoreaction was identified using a
VECTASTAIN Elite ABC kit (Vector
Laboratories, Burlingame, CA, USA) and
then marked with 3,30-diaminobenzidine
tetrahydrochloride (Dako) for 5 to 10
minutes. Finally, the sections were mounted
in Entellan medium (Merck, Kenilworth,
NJ, USA). Processed sections void of prima-
ry antibody were used as negative controls,
while healthy human skin specimens were
used as positive controls to validate the
antibodies.
Cell culture
Human fibroblasts were cultured in
Dulbecco’s modified Eagle medium with
10% fetal bovine serum and 1% penicil-
lin/streptomycin 1:1 in 25-cm2 plates and
then incubated at 37C in humidified air
with 5% carbon dioxide. The medium,
serum, and antibiotic mix were purchased
from Gibco (Thermo Fisher Scientific,
Waltham, MA, USA). When confluence
was reached, the cells were treated with
trypsin-EDTA 1% (Gibco), harvested, and
then centrifuged at 1200 rpm for 5 minutes.
The supernatant was removed and the cell
pellet was resuspended in 1 mL of complete
medium, positioned in 75-cm2 plates, and
incubated at 37C and 5% carbon dioxide
until 80% confluence was reached.
The Pelnac and Integra scaffolds were
pre-incubated in 24 plastic wells with cul-
ture medium at 37C in a 5% carbon diox-
ide humidified atmosphere. After 24 hours,
104 human fibroblasts cells were seeded in
the wells containing the scaffolds for 7 days.
Scanning electron microscopy
Samples of scaffolds were set with 2% glu-
taraldehyde in 0.1 M phosphate buffered
saline for 4 hours, then set in 1% osmium
tetroxide in the same buffer for 1 hour,
dehydrated in gradient ethanol, dried to
critical point (CPD 030; Bal-Tec AG,
Balzers, Liechtenstein), fixed to stubs with
colloidal silver, sprayed with gold using an
MED 010 coater (Bal-Tec AG), and then
analyzed with an FEI XL30 scanning elec-
tron microscope (FEI, Hillsboro, OR,
USA).
Statistical analysis
The Kolmogorov–Smirnov test revealed
non-normally distributed data; therefore,
all statistical analyses were carried out
according to a non-parametric approach.
To investigate the effectiveness of Pelnac
versus Integra, we calculated the improve-
ment in the average VAS score, Likert
score, and VSS score for each group at
each follow-up as well as the corresponding
median values and 95% confidence inter-
vals. The median values were then com-
pared using the Mann–Whitney U test.
The threshold for statistical significance
was set at p< 0.05. Repeatability is repre-
sented as a standard deviation to calculate
the differences between measurements using
SPSS version 16.0 software (SPSS Inc.,
Chicago, IL, USA).
Ethics statement
All procedures performed in studies involv-
ing human participants were in accordance
with the ethical standards of the institution-
al and/or national research committee and
with the 1964 Helsinki declaration and its
later amendments or comparable ethical
standards. Our institutional ethics commit-
tee (Comitato Etico Regionale Marche C.E.
R.M., Ancona, Italy) approved the study
design (protocol number: 2019-0275 OR).
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Results
Clinical results
Seventy-one patients were included in this
study. The two study groups (Pelnac,
n¼ 35; Integra, n¼ 36) (Table 3(a), (b))
were homogenous in terms of age (Pelnac,
54.3 16.11 years vs. Integra, 52.9 15.36
years) and lesion size (Pelnac, 67.3 80.66
cm2 vs. Integra, 75.4 114.23 cm2). In both
groups, the dressing was changed every 2
days, but the silicone film was maintained
until suture removal (2 weeks after Pelnac
implantation and up to 4 weeks after
Integra implantation). Two weeks following
surgery, there was evidence of substantial
wound exudate in the Pelnac grafts, causing
detachment of the silicone film most likely
due to early degradation of the collagen
sponge, which was not cross-linked.27 In
comparison, the wounds in the Integra
group remained largely dry and the silicone
film remained in place until removal by the
surgeon after 4 weeks. Nevertheless, we
observed temporary wound coverage in all
patients treated with Integra, with all
dermal templates fully engrafted in the
wound bed.
Clinically, all patients achieved satisfac-
tory recovery with no health-related issues.
All adherent bandages spontaneously
detached 5 days postoperatively in both
groups with the bandages remaining largely
dry and easily removable. The dermal
matrix and/or skin graft was well-unified in
most sites at the end of treatment (Figure 1).
The resultant biointegration allowed for
staged, definitive, and durable coverage of
the soft tissue. Evaluation of the collagen
color shift (from red to yellow) was feasible
because of the transparent silicone layer in
each DS; the color shifts indicated the dif-
ferent collagen maturation stages
(Figure 2).28 However, the patients treated
with Pelnac did not show the same clinical
results, especially in cases of extremely deep
wounds. Patients treated with both Integra
and Pelnac who underwent autografting
showed appropriate and rapid engraftment
without rejection (Figure 3).
The differences in contraction were eval-
uated after measuring the size of the artifi-
cial dermis. We assessed the wound
contracture by measuring the wound site
diameter when the silicone film was
removed. Pelnac showed significantly great-
er contraction than Integra after 2 weeks,
reaching 79.4% 20.16% of the initial area
at week 4. Contraction subsequently
reached a plateau phase (Table 4(a)).
Table 3(a). Sample distribution by age.
Treatment n Minimum age (years) Maximum age (years) Average age (years) SD
Pelnac 35 21 83 54.3 16.11
Integra 36 19 86 52.9 15.36
Total 71 19 86 53.5 15.63
Table 3(b). Sample distribution by wound area.
Treatment n Minimum WA Maximum WA Average WA SD
Pelnac 35 3 420 67.3 80.66
Integra 36 4 576 75.4 114.23
Total 71 3 576 71.4 98.49
SD, standard deviation; WA, wound area (cm2).
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Five patients in the Integra group and
five patients in the Pelnac group had deep
wounds (>1.5 cm) and did not undergo
autografting so that we could evaluate the
different wound contraction capacities with
respect to the depth of the lesion. All 10 of
these patients achieved rapid colonization
of the neoderm by keratinocytes with
stable and trophic scar formation after 40
days with no pathological hypertrophy. We
observed differences in the Wound Surface
Area Assessment among these patients with
respect to wound depth. The mean lesion
size was similar between the two groups
(Pelnac, 25.3 3.04 cm2 vs. Integra, 31.2
5.12 cm2). Table 4(b) shows that for
wounds measuring >1.5 cm, Integra pro-
duced a greater percentage reduction and
a shorter healing time than Pelnac. At the
short-term follow-up, 60% of the patients
had completely recovered with Integra com-
pared with 0% of the patients with Pelnac;
at the long-term follow-up, 100% of the
patients had completely recovered with
Integra compared with 0% of the patients
with Pelnac. Assessment was not possible in
the Integra group because macroscopic
observation of the ex vivo grafts confirmed
no occurrence of contracture, and all grafts
had the same diameter as in the initial
transplantation.
The difference in the healing time
between the groups was not statistically sig-
nificant. The VAS pain scores were also
similar between the two groups (Pelnac,
1.5 1.04 vs. Integra, 1.8 1.33) at both
the short- and long-term follow-ups
(Table 5(a)). Significant differences were
observed in patient self-estimation of com-
plete recovery at 4 weeks (short-term
follow-up) (Pelnac, 3.1 0.24 vs. Integra,
2.8 0.48; p¼ 0.003); however, no signifi-
cant differences were observed at 1 year
(long-term follow-up) (Pelnac, 3.6 0.48
vs. Integra, 3.4 0.51) (Table 5(b)). At
both the short- and long-term follow-ups,
statistically significant differences in the
VSS score were observed between the
groups and are shown in Table 6.
Significant differences were also noted in
the VSS scores (p< 0.05) as shown in the
box-and-whiskers plots in Figure 4(a) to (c).
Figure 1. Representative case of necrotizing
postpartum fasciitis treated with both dermal sub-
stitutes. (a, b) Outcome of necrotizing fasciitis after
several surgical debridement procedures. (c)
Immediate postoperative view after positioning of
dermal substitutes (yellow asterisk, Integra; blue
asterisk, Pelnac). (d) Two weeks following surgery,
there was evidence of substantial wound exudate in
the Pelnac grafts, causing detachment of the silicone
film in this group. In comparison, the wounds in the
Integra group remained largely dry and the silicone
film remained in place until removal by the surgeon
after 4 weeks. (e) The dermal matrix was well
unified in most sites at the end of treatment. (f) The
skin graft was well unified in most sites at the end of
treatment.
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Figure 2. (a–c) Visualization of the collagen color shift (from red to yellow) was feasible because of the
transparent silicone layer in each dermal substitute, indicating the different collagen maturation stages.
Patients treated with either Integra or Pelnac who underwent autografting showed appropriate and rapid
engraftment without rejection. (d) Thirty days after engraftment. (e) Sixty days after engraftment. (f) Ninety
days after engraftment.
Figure 3. Patients who did not undergo autografting achieved rapid colonization of the neoderm by
keratinocytes with stable and trophic scar formation. (a–c) Hand trauma treated with Pelnac. (d–f) Hand
trauma treated with Integra.
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Histological and immunohistochemical
analyses
Figure 5 shows histological sections of skin
wounds treated with an Integra or Pelnac
membrane stained with hematoxylin and
eosin 15 days after the treatment. The
images show a clear distinction between
the DS and the resident tissue.
In the tissue treated with Integra
(Figure 5(a)), partial and initial integration
Table 4(a). Differences in scar contraction.
Pelnac Integra
Median SD Median SD
Wound area (cm2)
Pre-op 67.3 80.66 75.4 114.23
2 weeks 47.8 52.14 66.7 90.78
4 weeks 15.5 26.36 43.6 72.32
1 year 5.1 14.24 22.1 54.97
Wound area contraction (%)
Pre-op vs. 2 weeks 24.9% 18.05% 0.1% 0.14%
Pre-op vs. 4 weeks 79.4% 20.16% 34.2% 33.33%
Pre-op vs. 1 year 64.7% 8.06% 74.7% 22.46%
For the two groups, the averages of the treated areas were calculated and the percentages of wound contraction were
calculated. Pre-op, preoperatively; SD, standard deviation.
Table 4(b). Differences in scar contraction.
4 weeks 1 year
Treatment Wound depth n % Reduction n % Reduction
Pelnac 1.5 cm 3 39% 3 89%
Integra 2 100%
Pelnac 2.0 cm 2 70% 2 86%
Integra 2 89% 2 100%
Pelnac 2.5 cm 0
Integra 1 100%
For the two groups, the percentages of wound reduction based on depth were calculated.
Table 5(a). Differences in pain-related VAS scores at short- and long-term follow up.
Treatment n Min Max Average SD
Integra
VAS score at 2 weeks 36 0 6 3.0 1.66
VAS score at 4 weeks 36 0 5 1.8 1.33
VAS score at 1 year 36 0 1 0.1 0.35
Pelnac
VAS score at 2 weeks 35 0 5 2.9 1.50
VAS score at 4 weeks 35 0 4 1.5 1.04
VAS score at 1 year 35 0 1 0.1 0.35
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between the tissue and the DS was observed
(Figure 5(a)). This area exhibited a massive
and localized inflammatory reaction
(Figure 5(c)) with the presence of granula-
tion tissue. Conversely, inflammatory infil-
tration was visibly reduced at the wound
edge, precisely where the DS had not yet
grafted with the tissue (Figure 5(a)).
The tissue treated with Pelnac exhibited
organic distribution of the collagen mem-
brane with a more advanced engraftment
than that in the Integra template. An
inflammatory reaction was also evident in
Pelnac-treated tissue (Figure 5(d)), and the
Pelnac-treated tissue displayed a moderate
level of inflammatory infiltration 15 days
after treatment. To confirm the presence
of inflammatory infiltration, the samples
underwent immunohistochemical analysis
for CD68 and ICAM-1, two inflammatory
markers. Figure 5(e) clearly shows the pres-
ence of CD68-positive inflammatory cells
that were particularly close to the DS
graft and around the vessels. Figure 5(f)
shows the results of the immunohistochem-
ical analysis for ICAM-1. Positive ICAM-1
labeling was found in proximity to the DS
graft and around the vessels. Moreover, the
Table 5(b). Differences in patient self-estimation on complete recovery scores at short and long-term
follow up.
Treatment n Min Max Average SD
Integra
Satisfied at 2 weeks 36 2 4 2.6 0.69
Satisfied at 4 weeks 36 2 4 2.8 0.48
Satisfied at 1 year 36 3 4 3.4 0.50
Pelnac
Satisfied at 2 weeks 34 2 4 2.8 0.50
Satisfied at 4 weeks 34 3 4 3.1 0.24
Satisfied at 1 year 34 3 4 3.6 0.48
VAS, visual analog scale; Min, minimum; Max, maximum; SD, standard deviation
Table 6. Differences in Vancouver Scar Scale score at short- and long-term follow-up.
Treatment Pigmentation Pliability Height Vascularity Total score
2 weeks
Pelnac 2.4 0.74 2.4 0.56 3.8 0.96 2.0 0.82 10.7 2.10
Integra 2.5 0.69 2.6 0.55 3.9 0.82 2.1 0.93 11.1 1.79
p 0.55 0.31 0.53 0.67 0.31
4 weeks
Pelnac 1.4 0.85 1.5 0.50 1.8 0.94 1.2 0.63 6.0 1.83
Integra 2.5 0.65 2.1 0.59 3.3 0.74 1.6 0.72 9.5 1.69
p <0.001* <0.001* <0.001* 0.001* <0.001*
1 year
Pelnac 0.6 0.88 0.7 0.44 0.8 1.16 0.1 0.35 2.3 1.81
Integra 1.2 0.87 1.5 0.77 2.7 1.03 0.9 0.59 6.3 1.66
p <0.001* <0.001* <0.001* <0.001* <0.001*
Data are presented as mean standard deviation. Comparisons between the two groups were performed using the
Mann–Whitney U test.
*p< 0.05 indicated statistical significance.
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Figure 4. At both the short-term and long-term follow-ups, statistically significant differences in the
Vancouver Scar Scale score were observed between the Pelnac and Integra groups. (a) Two weeks. (b) Four
weeks. (c) One year.
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images showed positivity for ICAM-1 in the
eccrine glands (both glands and ducts), but
not positivity for CD68. Figure 5(g) shows
the negative control for the
immunostaining. The histological section
was stained using the Van Gieson technique
and displayed evidence of newly formed
collagen fibers in the dermis treated with
Figure 5. Histological sections of skin wounds treated with (a) Integra or (b) Pelnac membrane stained
with hematoxylin and eosin 15 days after treatment. The images illustrate differentiation between the dermal
substitute and the resident tissue. The black arrows indicate the graft area between the dermal substitute
and the resident tissue (a, b; black arrows). The black asterisks indicate areas of partial integration between
the tissue and the dermal substitute, and the yellow asterisks indicate areas in which the dermal substitute
had not yet grafted with the tissue. (c, d) Higher magnification of (a) and (b), respectively; asterisks indicate a
localized inflammatory reaction. (e) Immunohistochemical analysis of CD68, confirming the presence of
inflammatory cells located close to the dermal substitute graft (arrows) and around the vessels (asterisk). (f)
Immunohistochemical analysis of intracellular adhesion molecule 1. Positive labeling was found close to the
dermal substitute graft (arrows), around the vessels (asterisk), and in the eccrine glands. (g) Negative control
for immunostaining. (a, b: magnification 4, scale bar¼ 300 mm; c–g: magnification 10, scale bar ¼150
mm).
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both Integra and Pelnac membranes
(Figure 6(a)–(d)). Organic collagen fibers
efficiently reconstructed the damaged struc-
tures. Moreover, immunohistochemical
analysis for collagen was performed to
investigate the effect of the DSs on dermal
remodeling fibers in the tissues (Figure 6
(e)). The immunohistochemical images con-
firmed the data obtained with Van Gieson
staining: both DSs contributed to the for-
mation of collagen fibers, and the tissue was
strongly positive for collagen type III
(Figure 6(f), (h)). Indeed, during the process
of wound healing, collagen type III acts as a
scaffold for fibroblast attachment, and high
secretion of collagen type III is promoted
by the DS graft.29 In the Integra-treated
tissue, we observed collagen type III fibers
specifically localized in the tissue engraft-
ment area with the DS, while in the
Pelnac-treated tissue, the collagen type III
fibers were homogeneously distributed
throughout the dermis. All samples were
negative for collagen type I, indicating
that prominent mature collagen fibers
(type I) were still not detectable 15 days
after treatment (Figure 6(i), (j)).
Consistent with the regenerative
response previously reported, both DSs
exhibited substantial angiogenic potential
and vascularization in the healing process,
indicating the development of granulation
tissue and the onset of the proliferative
stage of wound healing. Figure 7 shows
immunohistochemical analysis of VEGF
for the Integra and Pelnac membranes.
The images clearly demonstrate the forma-
tion of new vessels and microvessels distrib-
uted homogenously in the tissue with
significant positivity for VEGF (Figure 7
(b), (d)). The negative control for immunos-
taining analysis is shown in Figure 7(c) and
(f) with a marker-negative sample. The epi-
dermal area displayed a diffuse background
due to the staining procedure and was not
accounted for in the analysis of the results
considering the nonspecific positivity for
the marker.
Cell adhesion
A morphological study of human fibro-
blasts grown on the two DSs (Integra and
Figure 6. Newly formed collagen fibers in the
dermis treated with (a, b) Integra and (c, d) Pelnac.
Van Gieson staining showed that both dermal
substitutes contributed to the formation of colla-
gen fibers. (e–j) Immunohistochemical analysis of
tissue. The samples appeared strongly positive for
collagen type III (e, f: Integra; g, h: Pelnac). (f, h)
Higher magnification of (e) and (g), respectively;
arrows indicate the collagen type III fiber (f–h). (i, j)
All samples were negative for collagen type I. (a, c,
e, g, i, j: magnification 4, scale bar¼ 300 mm; b, d,
f: magnification 10, scale bar¼ 150 mm).
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Pelnac) was performed by scanning electron
microscopy after 7 days of cell culture.
Figure 8 shows images of cell-free and
cell-seeded scaffolding. We compared the
two DSs without adherent cells (Figure 8
(a)–(c) and Figure 8(e), (f)) via scanning
electron microscopy images and distin-
guished the bovine from porcine collagen
fibers contained in the Integra and Pelnac
scaffolds, respectively. In particular, the
bovine fibers produced a less smooth and
less wide-pored layer than did the porcine
collagen fibers. After 7 days of incubation,
cell attachment was visible between the col-
lagen scaffolds and the human fibroblasts in
both DSs. Moreover, scanning electron
microscopy images of the Integra scaffold
showed that the cells not only adhered to
the surface of the scaffold but also migrated
within, covering the existing pores (Figure 8
(b), (d)). The pore size for adhesion and
growth of cells normally ranges from 10
to 100 mm.30 The porosity in the Integra
scaffold was around 20 mm, which may
account for the adequate cell adhesion to
the scaffold. Despite the smoother surface
of the Pelnac scaffold, the cells covered and
infiltrated the scaffold with fibroblast-like
fusiform morphology (Figure 8(f), (h)).
No differences in cell growth or adhesion
were observed between the two DSs.
Discussion
Full-thickness skin defects resulting from
trauma, war-related injuries, oncologic
extirpation, burns, and chronic diseases
such as diabetes mellitus present unique
challenges to patients and reconstructive
surgeons.31 Local wound care, aggressive
debridement of infected/devitalized tissue,
and the reconstructive ladder (consisting
of the lower rung of skin grafting to more
advanced flap transfers) are all mainstay
therapies for full-thickness skin defects.
However, complex wounds involving large
surface areas in patients with limited donor
tissue and/or significant metabolic comor-
bidities (e.g., uncontrolled diabetes, sepsis,
acute/chronic soft tissue/bone infection)
increase the risk of skin graft loss and fail-
ure. Wound healing involves a multicellular
Figure 7. Both dermal substitutes exhibited significant angiogenic potential. The images show immuno-
histochemical analysis of vascular endothelial growth factor for (a, b) Integra and (d, e) Pelnac membrane. (c,
f) Negative control for staining. (a–d: magnification 10, scale bar¼ 100 mm; b–e: magnification 20, scale
bar¼ 50 mm).
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mechanism that includes coordination of
different cell types such as keratinocytes,
fibroblasts, endothelial cells, macrophages,
and platelets. These cells may migrate, infil-
trate, proliferate, and differentiate to yield
an inflammatory response that generates
new tissue and promotes subsequent
wound closure. Several authors have
reported intricate signaling coordination
within this complex process. Additionally,
several biologic and synthetic dermal and
epidermal regenerative modalities have
recently been investigated to treat full-
thickness skin defects and investigate the
fundamental characteristics of the biomate-
rial that closely resembles the natural fea-
tures of tissue.3,4,15,16,24,29,30,32
In the present study, we defined tissue-
engineered skin bio-constructs as DSs that
were acellular with xenogeneic synthetic
scaffolding and biodegradable material.
We observed differences in the composi-
tion, structure, and storage adequacy of
the two DSs. Integra is moist, gelatinous,
and translucent, while Pelnac is dry,
spongy, and white. Suppliers of DSs are
required to provide information regarding
the origins of the DSs. Integra possesses a
thickness and pore size of 2 mm and 70 to
200 mm, respectively, while these dimen-
sions for Pelnac are 3 mm and 70 to 110
mm, respectively. Investigations have been
conducted to better understand the most
appropriate conditions for DSs. Yannas32
determined the average pore diameter and
pore channel orientation. They found that
cells are able to infiltrate the scaffold and
bind to the ligands on the scaffold surface
at an average pore diameter of 20 to 120
mm. Moreover, Hori et al.33 illustrated the
differing morphological structures of DSs,
including the pore diameter and shape.
Integra may prevent the wound from con-
tracting and is efficient in releasing burn
contracture and re-sectioning giant nevi,
and it yields positive outcomes in extensive
trauma and full-thickness burns. Pelnac
may be indicated in wounds that are likely
to shrink, such as small dermal malignant
tumors and fingertip defects.
This observational study was performed
to compare Pelnac and Integra, classified as
dermal collagen matrices with identical
indications for use but different structures,
to understand their contribution in restor-
ing and regenerating post-traumatic inju-
ries. Wosgrau et al.29 conducted similar
comparative studies in mice. In each patient
of our study, we observed positive effects of
Figure 8. (a–d) Representative scanning electron
microscopy images of the bovine dermal substitute
Integra. (a, c) Integra scaffold (a: 200 mm, c: 50 mm).
(b, d) Integra scaffold 7 days after incubation of 104
human fibroblasts (b: 200 mm, d: 5 mm). (e–h)
Representative scanning electron microscopy
images of the porcine dermal substitute Pelnac. (e,
g) Pelnac scaffold without cells as control (e: 100
mm, g: 50 mm). (f, h) Pelnac scaffold 7 days after
incubation with 104 human fibroblasts (f: 100 mm, h:
50 mm).
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the DS in terms of improving the quality
and functionality of dermal reconstruction.
We assessed patient self-estimation of
recovery and pain on wound closure at
the short-term follow-up as well as the clin-
ical outcomes, particularly the healing time
after 40 days, and found no statistically sig-
nificant differences between the DSs.
Moreover, no differences were observed
between the two groups at the 1-year
follow-up, indicating satisfactory and con-
sistent clinical outcomes. However, the
Pelnac group showed more favorable
results in terms of the VSS score at the
short-term (4 weeks) and long-term (1-
year) follow-ups. Pelnac also resulted in
more significant wound contracture.
Interestingly, Integra provided a marked
reduction in deeper wound injuries.
Microscopic analysis of skin biopsy speci-
mens revealed cellular debris and skin
inflammatory infiltration with granulation
tissue. The presence of inflammatory infil-
trates confirmed our findings regarding
early granulation tissue containing primar-
ily type III collagen and little type I colla-
gen. Conversely, we examined the effect of
the Integra or Pelnac template on dermal
remodeling and observed reactive epider-
mal hyperplasia and dermal granulation
tissue as well as collagen fiber deposition
and newly formed vessels. Indeed, type III
collagen serves as scaffolding for fibroblast
attachment during wound healing, and high
secretion of collagen type III is promoted
by the graft of the DS.29 This histological
assessment is in line with the distinct color
shift of the collagen layer, examination of
which was made possible by the transparent
silicone layer in both the Pelnac and Integra
DS, during the first 2 weeks following
implantation. The biomaterial color shift
indicates recellularization and new vessel
formation. This allows for an efficient and
fundamental two-step technique with subse-
quent skin grafting. The color shift begins
in the first week following implantation,
revealing the diverse maturation phases of
the collagen, which span from red to vanil-
la/yellow.28 In fact, at this early stage, we
observed a change in the color of Pelnac
approximately 10 days before a change in
the color of Integra, suggesting that Pelnac
may become vascularized and recellularized
before Integra.
Pelnac is a DS that allows rapid neoan-
giogenesis and tissue regeneration with neo-
formed tissue architecture closer to the true
skin physiology. In contrast, Pelnac has
limited efficiency in deep wounds with or
without exposure to underlying structures
such as bone and tendon tissue. Integra is
more advantageous in deep wounds. No
difference were observed in the healing
time, but an important difference was
noted in wound contraction, which was
more marked in the injuries treated with
Pelnac than Integra.
Based on our observational data, we
propose a treatment algorithm that can
serve as a guideline for appropriate use of
these DSs (Figure 9). Both DSs are effective
and applicable in different clinical contexts.
Pelnac may be indicated in superficial
wounds of any size and in any part of the
body (with the exception of the face and
sites of articulation). Pelnac is not indicated
in burns, but it may be efficient in extensive
oncological resections. Integra may be used
for deep wounds of any size and in any part
of the body, and it is applicable in burns
and extensive oncological resections.
Limitations
This study has some limitations. Patients
with vascular ulcers, patients with diabetic
ulcers, and smokers were excluded.
Furthermore, the ulcer dimensions differed
between the study groups. Additionally, the
patients had an extensive age range.
Finally, the patient population was small,
and the follow-up was limited to 12
months. Larger series with longer
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follow-up periods are needed to validate the
optimal DS.
Conclusions
The efficacy of Integra and Pelnac is com-
parable in post-traumatic and iatrogenic
wounds based on the physiological similar-
ities of these DSs in terms of lesion type,
tissue regeneration, and healing processes.
Both DSs yielded positive outcomes in has-
tening and improving the quality and func-
tionality of skin reconstruction. Both
Pelnac and Integra are clinically applicable,
can be used successfully in surgery, and are
efficient in terms of healing time.
This randomized study demonstrated
differences between Integra and Pelnac
from long-term clinical and histological
perspectives in post-traumatic wounds, sug-
gesting that biomaterials influence the
wound microenvironment and tissue regen-
eration for a prolonged period after
implantation. Further studies are required
to better understand the different mecha-
nisms of action and impacts of DSs on clin-
ical outcomes.
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